TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983
TCL Archive In Brief: Treatment Reorganization Plan Due In November, Rauscher Says; Panel To Review Clinical Activities June 27, 1975